Last reviewed · How we verify
temocillin PK/PD in haemodialysis
temocillin PK/PD in haemodialysis is a Beta-lactam antibiotic (carboxypenicillin) Small molecule drug developed by AZ Sint-Jan AV. It is currently FDA-approved for Bacterial infections in patients with renal impairment undergoing haemodialysis, Gram-negative and gram-positive bacterial infections (general).
Temocillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Temocillin is a small molecule inhibitor of bacterial penicillin-binding protein, used to treat Gram-negative bacterial infections in patients with chronic renal failure requiring hemodialysis. The appropriateness of three times weekly temocillin treatment for severe Gram-negative infections in these patients is being studied in a clinical pharmacokinetic trial.
At a glance
| Generic name | temocillin PK/PD in haemodialysis |
|---|---|
| Sponsor | AZ Sint-Jan AV |
| Drug class | Beta-lactam antibiotic (carboxypenicillin) |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Temocillin is a carboxypenicillin with a broad spectrum of activity against gram-negative and gram-positive bacteria. It works by inhibiting cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. This study examines its pharmacokinetics and pharmacodynamics specifically in haemodialysis patients, where renal clearance is impaired.
Approved indications
- Bacterial infections in patients with renal impairment undergoing haemodialysis
- Gram-negative and gram-positive bacterial infections (general)
Common side effects
- Hypersensitivity reactions
- Gastrointestinal disturbances
- Phlebitis at injection site
- Elevated liver enzymes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- temocillin PK/PD in haemodialysis CI brief — competitive landscape report
- temocillin PK/PD in haemodialysis updates RSS · CI watch RSS
- AZ Sint-Jan AV portfolio CI
Frequently asked questions about temocillin PK/PD in haemodialysis
What is temocillin PK/PD in haemodialysis?
How does temocillin PK/PD in haemodialysis work?
What is temocillin PK/PD in haemodialysis used for?
Who makes temocillin PK/PD in haemodialysis?
What drug class is temocillin PK/PD in haemodialysis in?
What development phase is temocillin PK/PD in haemodialysis in?
What are the side effects of temocillin PK/PD in haemodialysis?
What does temocillin PK/PD in haemodialysis target?
Related
- Drug class: All Beta-lactam antibiotic (carboxypenicillin) drugs
- Target: All drugs targeting Penicillin-binding proteins (PBPs)
- Manufacturer: AZ Sint-Jan AV — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Bacterial infections in patients with renal impairment undergoing haemodialysis
- Indication: Drugs for Gram-negative and gram-positive bacterial infections (general)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing